Infliximab is a Medicine belongs to Monoclonal antibody group whose information about Brand can be referenced from   Book : Martindale    Page : 77   Edition : 38,

  ►   Brandname : Remicade

  ►  Strength : Injection with 100  mg,

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 656   Edition : 12,
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : IV infusion,
Reference :-   Book : Martindale    Page : 74   Edition : 38,

Dosing of Medicine differ in Adult & Pediatrics ↓


Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Rheumatoid arthiritis IV infusion 3 mg/kg Injection Repeated at 2 and 6 weeks, then every 8 weeks.
2 Ulcerative colitis IV infusion 5 mg/kg Injection
3 Ankylosing spondylitis IV infusion 5 mg/kg Injection repeated at 2 and 6 weeks and then every 6 to 8 weeks.
4 Plaque psoriasis IV infusion 5 mg/kg Injection Repeated at 2 and 6 weeks, then every 8 weeks.
5 Crohn’s disease IV infusion 5 mg/kg Injection Single dose.
6 Psoriatic arthiritis IV infusion 5 mg/kg Injection Single dose, repeated at 2 and 6 weeks and then every 8 weeks.

Ref :-  Book : Martindale    Page : 74   Edition : 38,




Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Juvenile idiopathic arthritis IV 3 10 mg/kg Injection

Ref :- Book : Nelson's textbook of Pediatrics    Page : 838   Edition : 19,
►  Side Effect : fever, chill, pruritus, Urticaria, dyspnoea, chest pain, hypertension, nausea, vomiting, abdominal pain, diarrhea, fatigue, Dizziness, headache, back pain, ,
Ref :-   Book : Martindale    Page : 75   Edition : 38, Martindale    Page : 76   Edition : 38,

►  Drug Interaction : Drug interaction of Infliximab is with Live Vaccines,  Anakinra ,
Ref :-   Book : Martindale    Page : 77   Edition : 38,


  ►    Mechanism of Drug Drug Interaction :  Live vaccines should not be given with infliximab or other drugs that inhibit TNF as the effect of such drugs on vaccine efficacy or the risk of infection transmission is unknown. The use of TNF inhibitors with the interleukin- 1 receptor antagonist anakinra may increase the risk of serious infections and neutropenia; such combinations are not recommended. A similar interaction has been seen with TNF inhibitors and the co-stimulation blocker abatacept,
Ref :-   Book : Martindale    Page : 77   Edition : 38,


►  Contraindication : jaundice or marked elevations in liver enzyme values.,
Ref :-   Book : Martindale    Page : 76   Edition : 38,
  ►  Mechanism of Action :   Infliximab IgG 1 monoclonal antibody that binds with high affinity to soluble and possibly membrane-bound TNF-α. Its mechanism of action probably is the same as that of adalimumab. Adalimumab is a fully human IgG 1 anti-TNF monoclonal antibody. This compound complexes with soluble TNF-α and prevents its interaction with p55 and p75 cell surface receptors. This results in down-regulation of macrophage and T-cell function. ,
Ref :-   Book : Basic & Clinical pharmacology    Page : 649,647   Edition : 12,

Pathway of Dietry Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- Turmeric with same pathwayAnother pathway, Turmeric with same pathwayAnother pathway,

  ►  Pathway with its reference as follows :-
  • Tumor necrosis factor (TNF-alpha) binding --- (Aggarwal, B., Gupta, S., & Sung, B. (2013). Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. British Journal Of Pharmacology, 169(8), 1672-1692. )
  • Curcumin block the tranformation, proliferation and in vasion of tumor cells. Curcumin suppresses the growth of several tumor cells lines, including drug resistant lines --- ( Wilken, R., Veena, M., Wang, M., & Srivatsan, E. (2011). Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Molecular Cancer, 10(1), 12 )
  • Tumor necrosis factor (TNF-alpha) binding --- (Aggarwal, B., Gupta, S., & Sung, B. (2013). Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. British Journal Of Pharmacology, 169(8), 1672-1692. )
  • Curcumin block the tranformation, proliferation and in vasion of tumor cells. Curcumin suppresses the growth of several tumor cells lines, including drug resistant lines --- ( Wilken, R., Veena, M., Wang, M., & Srivatsan, E. (2011). Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Molecular Cancer, 10(1), 12 )

  •   ►  URL -- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753829/, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055228/,


    Dietry Substance Interactions


    ​   ► This Medicine interact with :- NA



    ContraIndication Dietry Substance


    ​   ► This Medicine contraindicate with :- with aloe is contraindicated in case of intertinal obstruction ,acutely inflamed intestinal diseases,appendicitis & abdominal pain .muak,

      ►  Reference :-
  • PDR for Herbal medicines. (2000) (4th ed.). U.S.

  •   ►  URL -- http://www.travolekar.ru/arch/Pdr_for_Herbal_Medicines.pdf,

    ►   Route of Elimination :   NA


    ►    Plasma Half-life :   Min value :-   8 days,    Max value :-   9.5 days,
    Ref :-   Book : Martindale    Page : 77   Edition : 38,


    ►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA